

“High Throughput Drug Screening Facility for Neurodegenerative Disease”

AMENDMENT OF SOLICITATION NO.: RFP-NIH-NINDS-01-06

AMENDMENT NO.: 01

EFFECTIVE DATE: January 7, 2002

ISSUED BY:

National Institutes of Health
National Institute of Neurological Disorders and Stroke
Contracts Management Branch, DER
Neuroscience Center, MSC 9531
6001 Executive Boulevard, Suite 3287
Bethesda, Maryland 20892-9531

Point of Contact: Patricia S. Denney, Contracting Officer

NAME AND ADDRESS OF CONTRACTOR: To All Offerors

The above numbered solicitation is amended as set forth below. The hour and date specified for receipt of Offers remains unchanged, January 31, 2002, 4:30 P.M. (local time). Offers must acknowledge receipt of this amendment on each copy of the offer submitted. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

All other terms and conditions of the RFP remain unchanged.

DESCRIPTION OF AMENDMENT (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

Purpose: To include responses to technical questions submitted by potential offerors, and to issue a deadline date for submission of technical questions.

Technical Questions and Responses

The following are responses to formal questions submitted by potential offerors.

Question #1 - In describing the compound libraries, what is meant by in the “public domain”?

Answer - Active compounds identified under the contract will be supplied to the collaborating investigator who designed the primary assay. Therefore, these compounds should not be encumbered by proprietary considerations that would prevent their free access and use by collaborating investigators, or the publication of data derived from their use as research tools. In addition, the investigators should have access to additional supplies of these compounds as needed. Proposals should include a demonstration that active compounds will be freely available to collaborating investigators, including agreements with third parties to supply additional compounds if these are not commercially available by standard means.

Question #2 - What are the rights of the contractor for pursuing patents pertaining to novel uses of compounds discovered under the contract?

Answer - The NIH policy relating to the patenting of inventions and sharing of research tools developed with NIH funding will pertain to this contract. This policy can be found at http://ott.od.nih.gov/NewPages/Rtguide_final.html

IP agreements involving the assay conceived by the collaborating investigator will conform to the above NIH guidelines and, as described in the Statement of Work will be negotiated in good faith by the Collaborator and Contractor.

Question #3 - What Assays will be developed for screening under the contract?

Answer - The determination of which assays will be screened will be made once the contract is awarded. In consultation with NINDS, the contractor will have input into the final choice of assays to be screened. For the purposes of developing the proposal, the applicant should use the description of assays outlined in the Statement of Work and their own knowledge and experience with assays that are currently applicable for neurodegeneration research. The proposal should demonstrate experience and capabilities with as many types of assays relevant to neurodegeneration as possible.

Question #4 - What are the number and types of compounds to be screened? How many and what quantity of active compounds will be made available to collaborating investigators?

Answer - Details of this type are intentionally not specified in the solicitation to allow the offeror to propose the most appropriate approach to meet the goals detailed in the Statement of Work. The proposal should be developed based on the offeror's experience and capabilities relevant to the scope of the Statement of Work. The proposal should detail the number and types of compounds deemed by the offeror to be appropriate to the goals stated in the solicitation. The appropriateness of the proposal weighs heavily in the evaluation, as detailed in Section M of the Solicitation, Evaluation Factors for Award.

Question #5 - Will the contract pay for the compound libraries screened under the contract?

Answer - As stated in the solicitation, materials and supplies that are unique to the project will be paid for under the contract. This will include the cost of compounds purchased for use in the contracted screens. The proposed budget for compound libraries should be justified relative to the screening that will actually be performed under the contract. This proposed budget will be reviewed and analyzed in the context of the contracted project.

The deadline for receipt of technical questions is January 15, 2002, 2:00 P.M. Questions which, in your opinion, require clarification or correction by the Government, must be furnished in **writing** to the Contracting Officer. You are requested to submit (preferably via "e-mail") your questions to Patricia Denney. Questions must be mailed, e-mailed or faxed in sufficient time to be received in the contracting office on or before January 15, 2002 at 2:00 P.M., in order to allow a reply to reach all prospective offerors before submission of their proposals.

Email address: (pd22n@nih.gov).

Fax No.: (301) 402-4225

